FDA Warns Wild Arabic Herbs Over Cancer Claims for Herbal Product
FDA issued a warning letter to Wild Arabic Herbs after reviewing the company’s website and determining that its “Edral-17t” product was marketed as an unapproved new drug.
FDA cited claims that the product was a “Desert Herbs Formula for Prostate & Testicules [sic] Cancers” and was promoted for patients with prostate cancer, testicular malignancies, and other severe male reproductive conditions.
The agency also cited claims describing anticancer, antiproliferative, anti-metastatic, and selective cytotoxic effects, including statements that the product could inhibit uncontrolled cell division, prevent spread of malignant cells, and act against multiple cancer types.
FDA concluded that these claims established the product’s intended use as a drug. Because no approved FDA application was in effect for the product, FDA determined it was an unapproved new drug.
The firm was instructed to respond within 15 business days with corrective steps and measures to prevent recurrence.
MDP Perspective
This warning letter involves some of the highest-risk claim language in FDA enforcement: cancer treatment claims.
FDA has consistently treated cancer-related claims as a serious public health concern because patients may delay or avoid evidence-based medical care in favor of unapproved products.
For herbal, natural, supplement, and wellness companies, this letter is a clear warning. Claims involving cancer, metastasis, apoptosis, cytotoxicity, or disease treatment are not casual marketing language. They can create drug status immediately and invite FDA enforcement.
Links
Warning letter to Leading Edge Health, Inc.
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...
Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor
On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Class 1 Recall for HemosIL AcuStar HIT Antibody Test
HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...
